ALTOR BIOSCIENCE LLC has a total of 20 patent applications. It increased the IP activity by 800.0%. Its first patent ever was published in 2017. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are TRION PHARMA GMBH, KAHR MEDICAL LTD and GENAGON THERAPEUTICS AB.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 8 | |
#2 | WIPO (World Intellectual Property Organization) | 3 | |
#3 | Canada | 2 | |
#4 | China | 2 | |
#5 | EPO (European Patent Office) | 2 | |
#6 | Australia | 1 | |
#7 | Republic of Korea | 1 | |
#8 | Taiwan | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Peptides | |
#3 | Therapeutic chemical compounds | |
#4 | Fermentation | |
#5 | Microorganisms | |
#6 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Wong Hing C | 15 |
#2 | Zhu Xiaoyun | 9 |
#3 | Rhode Peter | 7 |
#4 | Li Qiongzhen | 5 |
#5 | Liu Bai | 4 |
#6 | Wong Hing | 3 |
#7 | Xu Wenxin | 2 |
#8 | Han Kai-Ping | 2 |
#9 | Connors Mark | 1 |
#10 | Marcus Warren | 1 |
Publication | Filing date | Title |
---|---|---|
WO2020150364A1 | Human immunodeficiency virus-specific t cell receptors | |
US2021008167A1 | T cell receptor fusions and conjugates and methods of use thereof | |
TW202003011A | Anti-PDL1, IL-15 and TGF-beta receptor combination molecules | |
WO2019046313A1 | Il-15-based fusions to il-7 and il-21 |